ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma; Clinical Development Plan on Track.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- ZIOPHARM Oncology, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: ZIOP), announced today dosing of the first patient in a phase I/II trial with ZIO-201, the Company's proprietary alkylating drug. The study will take place at leading cancer centers in the U.S. and the U.K., including The University of Texas M. D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New , University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. and the Royal Marsden Hospital. ZIO-201 (isophosphoramide mustard or IPM (1) (Impressions Per Minute) Generally refers to document scanners that scan both sides of the page at the same time. Thus, a scanner that scans at 100 ppm (pages per minute) can provide 200 ipm. See ppm and document scanner. ) is the active metabolite active metabolite Therapeutics A drug metabolite with therapeutic activity similar to the parent compound, which must be considered in therapeutic pharmacokinetics of ifosfamide, a frequently used treatment for sarcoma sarcoma (särkō`mə), highly malignant tumor arising in connective- and muscle-cell tissue. It is the result of oncogenes (the cancer causing genes of some viruses) and proto-oncogenes (cancer causing genes in human cells). . Due to the high toxicity of ifosfamide, mesna is frequently co-administered as an "uroprotective" agent. The Company expects ZIO-201 to be a useful agent that will deliver therapeutic activity at higher doses with less toxicity than that associated with ifosfamide. An ongoing phase I study suggests ZIO-201 may be given at doses that deliver more of the active metabolite (IPM) than can be achieved using ifosfamide. Currently at cohort 13, the maximum tolerated dose has not yet been reached. Additionally, one subject has stable disease for more than one year, and no mesna has been administered. "The potential to safely deliver ZIO-201 at high doses compared with ifosfamide represents a potential advance in the treatment of this disease," commented Robert Benjamin, M.D., Clinical Medical Director, Sarcoma Center at M. D. Anderson Cancer Center. "We know that high-dose ifosfamide is an effective drug in treating patients with sarcoma." In addition, the Company currently anticipates conducting phase II studies in adult and pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. sarcoma, along with an exploratory phase II trial in lymphoma. About ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com. Forward-Looking Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement: This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and the Company's reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion